Show simple item record

dc.contributor.authorPérez-Valero, I
dc.contributor.authorGonzález-Baeza, A
dc.contributor.authorEstébanez, M
dc.contributor.authorMontes, M
dc.contributor.authorBayon, C
dc.contributor.authorPulido, F
dc.contributor.authorCambrón, I
dc.contributor.authorBernardino, J
dc.contributor.authorZamora, F
dc.contributor.authorMonge Corella, Susana 
dc.contributor.authorGaya, F
dc.contributor.authorLagarde, M
dc.contributor.authorRubio, R
dc.contributor.authorHernando, A
dc.contributor.authorGonzález-García, J
dc.contributor.authorArnalich, F
dc.contributor.authorArribas, J
dc.date.accessioned2021-04-29T10:38:04Z
dc.date.available2021-04-29T10:38:04Z
dc.date.issued2012-11
dc.identifier.citationJournal of the International AIDS Society 2012,15(Suppl 4):18179es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12821
dc.language.isoenges_ES
dc.publisherWiley Open Accesses_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleProlonged treatment with boosted protease inhibitor monotherapy is not associated with a higher rate of neurocognitive impairment than triple drug ARTes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.format.volume15es_ES
dc.format.number6 (Suppl 4)es_ES
dc.identifier.doi10.7448/IAS.15.6.18179es_ES
dc.description.peerreviewedSíes_ES
dc.identifier.e-issn1758-2652es_ES
dc.relation.publisherversionhttp://dx.doi.org/10.7448/IAS.15.6.18179es_ES
dc.identifier.journalJournal of the International AIDS Societyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Name:
ProlongedTreatmentWithBoosted_ ...
Size:
182.7Kb
Format:
PDF
FilesOpen

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional